Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population

2017 United European Gastroenterology Journal 5;1 (76-85)

BACKGROUND: The FibroScan(R) XL probe reduces failure of liver stiffness measurement (LSM) and unreliable results in obese patients. OBJECTIVE: The objective of this article is to evaluate the accuracy of controlled attenuation parameter (CAP) obtained using the XL probe for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: Adult NAFLD patients with a liver biopsy within six months were included and were examined with the FibroScan(R) M and XL probes. Histopathological findings were reported according to the Non-Alcoholic Steatohepatitis Clinical Research Network Scoring System. Participants who did not have fatty liver on ultrasonography were recruited as controls. RESULTS: A total of 57 NAFLD patients and 22 controls were included. The mean age of the NAFLD patients and controls was 50.1 +/- 10.4 years and 20.2 +/- 1.3 years, respectively (p = 0.000). The mean body mass index was 30.2 +/- 5.0 kg per m2 and 20.5 +/- 2.4 kg per m2, respectively (p = 0.000). The distribution of steatosis grades were: S0, 29%; S1, 17%; S2, 35%; S3, 19%. The AUROC for estimation of steatosis grade >/= S1, S2 and S3 was 0.94, 0.80 and 0.69, respectively, using the M probe, and 0.97, 0.81 and 0.67, respectively, using the XL probe. CONCLUSION: CAP obtained using the XL probe had similar accuracy as the M probe for the estimation of hepatic steatosis in NAFLD patients.

Pubmed : 28405325